Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Future Outlook: Strong Growth Expected Toward $32.86 Billion by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the glucagon-like peptide (glp)-1 agonists weight loss drugs market from 2026–2035 with trusted insights from The Business Research Company
What is the estimated market size of the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market by the end of 2030?
The market size for glucagon-like peptide (glp)-1 agonists weight loss drugs has experienced rapid expansion in recent years. This market is projected to expand from $15.5 billion in 2025 to $18.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.3%. Historically, this expansion has been driven by factors such as an increase in obesity prevalence, advancements in diabetes medications, the burden of lifestyle diseases, the initial application of GLP-1 in diabetes, and various healthcare awareness initiatives.
The market size for glucagon-like peptide (glp)-1 agonists weight loss drugs is poised for significant expansion in the coming years. It is forecast to attain $32.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.2%. This growth during the forecast period can be attributed to factors such as the approval of new glp-1 medications, an increase in obesity clinics, broader insurance coverage, a focus on long-term weight management, and rising global obesity rates. Prominent trends anticipated in this period include an escalating demand for pharmacological weight management, increased utilization of injectable weight loss drugs, the wider adoption of glp-1 therapies beyond diabetes, the growth of obesity treatment programs, and improved patient adherence to extended therapy.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp
What Drivers Are Shaping Future Opportunities In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The growing occurrence of obesity is projected to drive the glucagon-like peptide (GLP)-1 agonist weight loss drugs market forward. This medical condition is characterized by an excessive accumulation of body fat, posing health risks. Rates of obesity are increasing as a result of unhealthy eating habits, including consuming more fast food and sugary beverages, which often lack proper nutrition and balance. With a continuous increase in individuals affected by obesity and its complications, the need for effective treatment options is escalating, consequently boosting the utilization of glucagon-like peptide (GLP)-1 agonist weight loss drugs due to their established effectiveness in promoting weight loss and improving metabolic health. For instance, in May 2025, the Office for Health Improvement and Disparities, a UK-based government body, reported that an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity from 2023 to 2024, marking an increase from 64.0% in 2022 to 2023. Thus, the increasing prevalence of obesity is a key driver for the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market.
Which Segments Are Gaining Traction In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
The glucagon-like peptide (glp)-1 agonists weight loss drugs market covered in this report is segmented –
1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs
2) By Route of Administration: Parenteral, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
Subsegments:
1) By Semaglutide: Ozempic, Wegovy, Rybelsus
2) By Liraglutide: Saxenda, Victoza
3) By Tirzepatide: Mounjaro, Zepbound
4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide
How Are New Market Trends Shaping The Landscape Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
Leading companies within the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are developing advanced obesity treatment solutions to enhance efficacy and improve patient outcomes. Obesity treatment solutions encompass therapies that replicate the GLP-1 hormone’s action to regulate appetite, increase satiety, and facilitate weight reduction. These medications assist in managing obesity by improving metabolic function and supporting sustained weight control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, obtained US Food and Drug Administration approval for Zepbound, a drug for chronic weight management in adults with obesity or overweight who have related health conditions such as type 2 diabetes or sleep apnea. The medication operates by activating GIP and GLP-1 hormone receptors to curb appetite and boost metabolic function.
Who Are The Top-Performing Companies In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In Recent Years?
Major companies operating in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc, Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd
Access The Complete Report For Deeper Market Insights:
How Does The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Perform Across Major Global Regions?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2025. The regions covered in the glucagon-like peptide (glp)-1 agonists weight loss drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp
Browse Through More Reports Similar to the Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market 2026, By The Business Research Company
Peptide Based Metabolic Disorders Therapeutics Market Report 2026
Glucagon Like Peptide 1 Market Report 2026
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report
Weight Loss Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/weight-loss-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
